•  
  •  
 

Subject Area

Pediatrics

Article Type

Original Study

Abstract

Objective To shed light on the possible role of apelin-36 in psoriasis and to evaluate the propensity of the psoriatic population to a prediabetic condition through determining the serum level of apelin-36 in psoriatic patients. Background Psoriasis is a chronic, inflammatory skin disease characterized by the formation of sharply demarcated, scaly, erythematous plaques. Research over the last few decades has shown the relation of psoriasis pathogenesis to systemic diseases and metabolic syndrome (obesity, hypertension, dyslipidemia, and diabetes). Patients and methods This case–control study was carried out on 60 cases with psoriasis and 60 age-matched and sex-matched healthy individuals as a control group. All were subjected to full history taking, general examination, local examination with determination of site of lesions and assessment of psoriasis area and severity index score. Serum apelin-36 and glycosylated hemoglobin (HbA1c) was done for all cases and control (P < 0.001). Results The serum level of apelin-36 was lower in psoriatic patients than controls (mean: 37.17 ± 75.93 vs. 221.85 ± 483.40 ng/ml; P = 0.028), while the blood level of HbA1c was higher in psoriatic patients than controls (mean: 5.98 ± 0.62 vs. 5.55 ± 0.54%; P < 0.001). The best cutoff value of apelin-36 in the prediction of prediabetic cases in psoriatic patients was lesser than or equal to 37.50 ng/ml, with a sensitivity of 94.4%, specificity of 66.7%, and total accuracy of 91.7%. Conclusion Apelin-36 serum level was decreased and HbA1c was increased in psoriasis patients that indicated impairment in glucose metabolism in psoriatic patients.

Download

Share

COinS